Abstract
SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have